Pfizer Inc. aims to expand its vaccine business by becoming a leader in the new gene-based technology behind its successful Covid-19 injections.
Pfizer will develop new vaccines using the technology, called mRNA, to attack other viruses and pathogens beyond the coronavirus, Chief Executive Officer Albert Bourla said in an interview. He said the company’s scientists and engineers gained a decade of experience in the last year working on the Covid-19 vaccine with Germany’s BioNTech SE, and are ready to search for mRNAs themselves.
“There is a technology that has been shown to have dramatic impact and dramatic potential,” Bourla said. “We are the best positioned company at the moment to take the next step due to our size and our experience.”
Pfizer will increase R&D in the technology, including adding at least 50 employees whose assignments will include mRNA, and will take advantage of the new mRNA manufacturing network it assembled last year to compete.
“Now we are ahead and we plan to keep the gap,” he said of the mRNA vaccine market.